Alan Anticevic
Associate Professor of Psychiatry and Psychology at Yale School of Medicine
Data updated
Research Footprint
Alan Anticevic appears in 6 tracked papers (2016–2024), most studied alongside Ketamine, Psilocybin and Placebo, across Neuroimaging & Brain Measures, Depressive Disorders and Healthy Volunteers.
Most-cited paper: Ketamine Treatment and Global Brain Connectivity in Major Depression (304 citations).
Frequent co-authors: Katrin Preller, Franz Vollenweider and John Krystal.
Background & Research
Alan Anticevic is a Croatian neuroscientist and Yale faculty member whose research focuses on the neural circuitry of psychiatric illness, functional connectivity, and computational neuroimaging methods. He trained in clinical psychology and cognitive neuroscience at Washington University in St. Louis and completed clinical neuropsychology internship training at Yale, where he later joined the psychiatry faculty. He co-directs Yale’s Division of Neurocognition, Neurocomputation, and Neurogenetics (N3) and studies how brain network dynamics relate to cognition, affect, and pharmacological interventions.
Key Impact
He is a leading neuroimaging and computational psychiatry researcher whose work includes pharmacological fMRI studies of ketamine and psychedelics, helping map how these compounds alter brain connectivity and subjective experience.
Collaboration Network
16 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Alan Anticevic is associated with.
VA Connecticut Healthcare System
governmentThe VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.
View stakeholder →Yale University
academicIn 2016, the 'Yale Psychedelic Science Group' was established as a forum where clinicians and scholars from across Yale can learn about and discuss the rapidly re-emerging field of psychedelic science and therapeutics in an academically rigorous manner. Research with psychedelics is also underway at Yale School of Medicine. A recent study at the university found that a single dose of psilocybin can cause structural changes in the brain that counteract symptoms of depression.
View stakeholder →